Who are factor ix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hemlibra, Factor IX recovery, Albutrepenonacog Alfa 1 UNT [IDELVION], Recombinant factor IX, RIXUBIS: On-Demand, RIXUBIS: Prophylaxis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/factor-ix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

factor ix — Competitive Intelligence Brief

factor ix (factor ix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed coagulation Factor IX Small molecule Live · refreshed every 30 min

Target snapshot

factor ix (factor ix) — National Heart, Lung, and Blood Institute (NHLBI). REBINYN replaces missing coagulation Factor IX and slows its removal from circulation through PEGylation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
factor ix TARGET	factor ix	National Heart, Lung, and Blood Institute (NHLBI)	marketed		coagulation Factor IX
Hemlibra	EMICIZUMAB	Roche	marketed		Coagulation factor IX	2017-01-01
Factor IX recovery	Factor IX recovery	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Coagulation factor replacement	Factor IX (coagulation factor IX)
Albutrepenonacog Alfa 1 UNT [IDELVION]	Albutrepenonacog Alfa 1 UNT [IDELVION]	National Taiwan University Hospital	marketed	Recombinant coagulation factor (Factor IX fusion protein)	Factor IX (coagulation factor IX)
Recombinant factor IX	Recombinant factor IX	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation factor IX (F9)
RIXUBIS: On-Demand	RIXUBIS: On-Demand	Baxalta now part of Shire	marketed	Recombinant coagulation factor	Coagulation Factor IX (FIX)
RIXUBIS: Prophylaxis	RIXUBIS: Prophylaxis	Baxalta now part of Shire	marketed	Recombinant coagulation factor	Coagulation Factor IX (FIX)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). factor ix — Competitive Intelligence Brief. https://druglandscape.com/ci/factor-ix. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab